The aims of nonclinical safety pharmacology evaluations are three-fold:
* To protect Phase I clinical trial volunteers from acute adverse effects of drugs
* To protect patients (including patients participating in Phase II and III clinical trials)
* To minimize risks of failure during drug development and post-marketing phases due to undesirable pharmacodynamic effects